Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results

被引：1

作者：

Liu, Joyce ^{[1
]}

O'Malley, David ^{[2
,3
]}

Van Nieuwenhuysen, Els ^{[4
]}

Moore, Kathleen ^{[5
]}

Hamilton, Erika ^{[6
]}

Yeku, Oladapo ^{[7
]}

Bouberhan, Sara ^{[7
]}

Hou, June ^{[8
]}

Schroeder, David ^{[9
]}

Wang, Bin ^{[10
]}

Yoo, Suk-Young ^{[10
]}

Govindraj, Shilpa ^{[11
]}

Brouwer-Visser, Jurriaan ^{[12
]}

Peterman, Mary ^{[13
]}

Schmidt, Tamara ^{[13
]}

Barnes, Brigid ^{[13
]}

Lowy, Israel ^{[13
]}

Uldrick, Thomas ^{[13
]}

Miller, Elizabeth ^{[13
]}

O'Cearbhaill, Roisin ^{[14
,15
]}

机构：

[1] Dana Farber Canc Inst, Div Gynecol Oncol, Boston, MA 02115 USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] James Canc Ctr, Div Gynecol Oncol Obstet & Gynecol, Columbus, OH USA

[4] Leuven Canc Inst, Gynaecol & Obstet, Leuven, Belgium

[5] Univ Oklahoma, Sarah Cannon Res Inst, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[6] Tennessee Oncol Breast & Gynecol Canc Res, Sarah Cannon Res Inst, Nashville, TN USA

[7] Massachusetts Gen Hosp, Gynecol Oncol Program, Boston, MA USA

[8] Columbia Univ, Med Ctr, Div Gynecol Oncol, New York, NY USA

[9] Grand Hop Charleroi, Serv Oncol Hematol, Charleroi, Belgium

[10] Regeneron Pharmaceut Inc, Biostat, Tarrytown, NY USA

[11] Regeneron Pharmaceut Inc, Global Patient Safety, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Precis Med, Tarrytown, NY USA

[13] Regeneron Pharmaceut Inc, Oncol Clin Dev, Tarrytown, NY USA

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Weill Cornell Med Coll, Gynecol Med Oncol Serv, New York, NY USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO011LBA

引用

页码：A9 / A10

页数：2

共 50 条

[1] Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
O'Cearbhaill, R. E.
Moore, K. N.
Yeku, O.
Liu, J. F.
Bouberhan, S.
Hamilton, E. P.
Hou, J. Y.
Van Nieuwenhuysen, E.
Papadimitriou, K.
Yoo, S-Y.
Govindraj, S.
Brouwer-Visser, J.
Peterman, M.
Schmidt, T.
Barnes, B.
Madia, P.
Zhu, M.
Uldrick, T. S.
Miller, E. A.
O'Malley, D.
ANNALS OF ONCOLOGY, 2023, 34 : S516 - S517
[2] A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer
Van Nieuwenhuysen, Els
Bouberhan, Sara
Papadimitriou, Konstantinos
Arend, Rebecca Christian
Lee, Jung-Yun
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
You, Benoit
Martin, Antonio Gonzalez
Michels, Judith
Mileshkin, Linda R.
Lee, Yeh Chen
Miller, Rowan
Yoo, Suk-Young
Peterman, Mary Jane
Schmidt, Tamara
Knorr, David
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
Moore, Kathleen N.
Bouberhan, Sara
Hamilton, Erika P.
Liu, Joyce F.
O'Cearbhaill, Roisin Eilish
O'Malley, David M.
Papadamitriou, Konstantinos
Schroder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Peterman, Mary Jane
Goncalves, Priscila Hermont
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas S.
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
Moore, Kathleen
Bouberhan, Sara
Hamilton, Erika
Liu, Joyce
O'Cearbhaill, Roisin
O'Malley, David
Papadimitriou, Konstantinos
Schroder, David
Van Nieuwenhuysen, Els
Yoo, Suk-Young
Wang, Bin
Peterman, Mary
Goncalves, Priscila
Schmidt, Tamara
Zhu, Min
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A254 - A255
[5] A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update
Liu, Joyce
O'Malley, David
Van Nieuwenhuysen, Els
O'Cearbhaill, Roisin
Bouberhan, Sara
Moore, Kathleen
Hou, June
Hamilton, Erika
Yoo, Suk-Young
Wang, Bin
Peterman, Mary
Schmidt, Tamara
Knorr, David
Lowy, Israel
Uldrick, Thomas
Miller, Elizabeth
GYNECOLOGIC ONCOLOGY, 2024, 190 : S284 - S284
[6] Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
Van Nieuwenhuysen, E.
O'Malley, D.
O'Cearbhaill, R. E.
Moore, K. N.
Hamilton, E. P.
Yeku, O.
Bouberhan, S.
Hou, J. Y.
Yoo, S-Y.
Brouwer-Visser, J.
Cheung, H. K.
Peterman, M.
Goncalves, P.
Schmidt, T.
Zhu, M.
Lowy, I.
Rowlands, T.
Uldrick, T. S.
Miller, E. A.
Liu, J. F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S784 - S784
[7] TRANSLATIONALFINDINGSFROM THE ONGOINGFIRST--IN--HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER: REGIMEN SELECTION.
Zhu, M.
Crawford, A.
Retter, M.
Toroghi, M. Khaksar
Conrado, D.
Brouwer--Visser, J.
Krueger, P.
Meng, X.
Davis, J.
Peterman, M.
Uldrick, T.
Miller, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S46 - S46
[8] Exposure-biomarker analyses for cytokine release syndrome or infusion-related reaction, pain, and cytokine concentrations in serum during treatment with ubamatamab, a MUC16xCD3 bispecific antibody, among patients with recurrent ovarian cancer
Madia, Priyanka
Brouwer-Visser, Jurriaan
Qin, Qiao
Conrado, Daniela
Davis, John
Uldrick, Thomas
Peterman, Mary
Miller, Elizabeth
Zhu, Min
GYNECOLOGIC ONCOLOGY, 2024, 190 : S287 - S287
[9] EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)
Madia, P.
Conrado, D.
Brouwer-Visser, J.
Qin, Q.
Davis, J.
Uldrick, T.
Peterman, M.
Miller, E.
Zhu, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S65 - S65
[10] TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION
Zhu, M.
Crawford, A.
Retter, M.
Toroghi, M. Khaksar
Conrado, D.
Brouwer-Visser, J.
Krueger, P.
Meng, X.
Davis, J.
Peterman, M.
Uldrick, T.
Miller, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S59 - S59

← 1 2 3 4 5 →